Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT ID: NCT01573598

Last Updated: 2015-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1219 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Dose-matched placebo capsules, oral administration

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo given orally, once per day

Vilazodone 20mg

Vilazodone tablets, 20 mg per day, oral administration

Group Type EXPERIMENTAL

Vilazodone

Intervention Type DRUG

Vilazodone, 20 mg per day, oral administration

Vilazodone 40mg

Vilazodone tablets, 40 mg per day, oral administration

Group Type EXPERIMENTAL

Vilazodone

Intervention Type DRUG

Vilazodone, 40 mg once per day, oral administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Matching placebo given orally, once per day

Intervention Type DRUG

Vilazodone

Vilazodone, 20 mg per day, oral administration

Intervention Type DRUG

Vilazodone

Vilazodone, 40 mg once per day, oral administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Viibryd Viibryd

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women, 18-70 years of age
* Currently meet the DSM-IV-TR criteria for Major Depressive Disorder
* The patient's current major depressive episode must be at least 8 weeks and no longer than 18 months in duration

Exclusion Criteria

* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control
* Patients with a history of meeting DSM-IV-TR criteria for:

* any manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode;
* any depressive episode with psychotic or catatonic features;
* panic disorder with or without agoraphobia;
* obsessive-compulsive disorder;
* Schizophrenia, schizoaffective, or other psychotic disorder;
* bulimia or anorexia nervosa;
* presence of borderline personality disorder or antisocial personality disorder; h. mental retardation, dementia, amnesia, or other cognitive disorders
* Patients who are considered a suicide risk
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Forest Laboratories

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carrie Reichley

Role: STUDY_DIRECTOR

Forest Research Institute, a subsidiary of Actavis plc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Forest Investigative Site 030

Beverly Hills, California, United States

Site Status

Forest Investigative Site 012

Chino, California, United States

Site Status

Forest Investigative Site 022

Costa Mesa, California, United States

Site Status

Forest Investigative Site 017

Los Angeles, California, United States

Site Status

Forest Investigative Site 005

Newport Beach, California, United States

Site Status

Forest Investigative Site 027

Riverside, California, United States

Site Status

Forest Investigative Site 026

San Diego, California, United States

Site Status

Forest Investigative Site 016

Cromwell, Connecticut, United States

Site Status

Forest Investigative Site 029

Hartford, Connecticut, United States

Site Status

Forest Investigative Site 020

Doral, Florida, United States

Site Status

Forest Investigative Site 007

Fort Lauderdale, Florida, United States

Site Status

Forest Investigative Site 006

Fort Myers, Florida, United States

Site Status

Forest Investigative Site 004

Hallandale, Florida, United States

Site Status

Forest Investigative Site 039

Jacksonville, Florida, United States

Site Status

Forest Investigative Site 008

Jacksonville Beach, Florida, United States

Site Status

Forest Investigative Site 015

Leesburg, Florida, United States

Site Status

Forest Investigative Site 035

Orlando, Florida, United States

Site Status

Forest Investigative Site 001

West Palm Beach, Florida, United States

Site Status

Forest Investigative Site 034

Winter Park, Florida, United States

Site Status

Forest Investigative Site 019

Hoffman Estates, Illinois, United States

Site Status

Forest Investigative Site 021

Indianapolis, Indiana, United States

Site Status

Forest Investigative Site 003

Boston, Massachusetts, United States

Site Status

Forest Investigative Site 013

Weymouth, Massachusetts, United States

Site Status

Forest Investigative Site 028

Rochester Hills, Michigan, United States

Site Status

Forest Investigative Site 038

Brooklyn, New York, United States

Site Status

Forest Investigative Site 037

New York, New York, United States

Site Status

Forest Investigative Site 032

New York, New York, United States

Site Status

Forest Investigative Site 009

New York, New York, United States

Site Status

Forest Investigative Site 014

Durham, North Carolina, United States

Site Status

Forest Investigative Site 025

Oklahoma City, Oklahoma, United States

Site Status

Forest Investigative Site 024

Oklahoma City, Oklahoma, United States

Site Status

Forest Investigative Site 036

Memphis, Tennessee, United States

Site Status

Forest Investigative Site 023

Dallas, Texas, United States

Site Status

Forest Investigative Site 011

Houston, Texas, United States

Site Status

Forest Investigative Site 010

Plano, Texas, United States

Site Status

Forest Investigative Site 002

San Antonio, Texas, United States

Site Status

Forest Investigative Site 031

Richmond, Virginia, United States

Site Status

Forest Investigative Site 033

Bellevue, Washington, United States

Site Status

Forest Investigative Site 103

Pleven, , Bulgaria

Site Status

Forest Investigative Site 104

Plovdiv, , Bulgaria

Site Status

Forest Investigative Site 106

Sofia, , Bulgaria

Site Status

Forest Investigative Site 102

Sofia, , Bulgaria

Site Status

Forest Investigative Site 304

Helsinki, Etelä-Suomen Lääni, Finland

Site Status

Forest Investigative Site 305

Helsinki, Etelä-Suomen Lääni, Finland

Site Status

Forest Investigative Site 301

Helsinki, Etelä-Suomen Lääni, Finland

Site Status

Forest Investigative Site 303

Rauma, Länsi-Suomen Lääni, Finland

Site Status

Forest Investigative Site 302

Kuopio, , Finland

Site Status

Forest Investigative Site 306

Turku, , Finland

Site Status

Forest Investigative Site 307

Turku, , Finland

Site Status

Forest Investigative Site 401

Hanover, Lower Saxony, Germany

Site Status

Forest Investigative Site 405

Dresden, Saxony, Germany

Site Status

Forest Investigative Site 403

Berlin, , Germany

Site Status

Forest Investigative Site 408

Berlin, , Germany

Site Status

Forest Investigative Site 407

Chemnitz, , Germany

Site Status

Forest Investigative Site 402

Hüttenberg, , Germany

Site Status

Forest Investigative Site 409

Münster, , Germany

Site Status

Forest Investigative Site 404

Nuremberg, , Germany

Site Status

Forest Investigative Site 406

Westerstede, , Germany

Site Status

Forest Investigative Site 602

Bucharest, București, Romania

Site Status

Forest Investigative Site 601

Arad, , Romania

Site Status

Forest Investigative Site 603

Iași, , Romania

Site Status

Forest Investigative Site 705

Petrozavodsk, Kareliya, Respublika, Russia

Site Status

Forest Investigative Site 701

Moscow, , Russia

Site Status

Forest Investigative Site 804

Belgrade, Beograd, Serbia

Site Status

Forest Investigative Site 806

Niš, Nišava, Serbia

Site Status

Forest Investigative Site 801

Belgrade, , Serbia

Site Status

Forest Investigative Site 802

Belgrade, , Serbia

Site Status

Forest Investigative Site 803

Kragujevac, , Serbia

Site Status

Forest Investigative Site 805

Kragujevac, Šumadija, Serbia

Site Status

Forest Investigative Site 903

Kherson, Kherson Oblast, Ukraine

Site Status

Forest Investigative Site 905

Luhansk, Luhansk Oblast, Ukraine

Site Status

Forest Investigative Site 901

Lviv, Lviv Oblast, Ukraine

Site Status

Forest Investigative Site 906

Odesa, Odesa Oblast, Ukraine

Site Status

Forest Investigative Site 902

Dnipropetrovsk, , Ukraine

Site Status

Forest Investigative Site 904

Simferopol, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Finland Germany Romania Russia Serbia Ukraine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VLZ-MD-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.